Literature DB >> 19355826

Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm.

Salvatore Sorrenti1, Pierpaolo Trimboli, Antonio Catania, Salvatore Ulisse, Enrico De Antoni, Massimino D'Armiento.   

Abstract

BACKGROUND: Thyroid nodules that are read on cytology as follicular or Hürthle cell neoplasms (FN and HN, respectively) and indeterminate for malignancy require surgery to differentiate benign from malignant nodules. We analyzed FN and HN with indeterminate cytology to determine if there were differences in the rate and types of thyroid malignancy and if the rate of thyroid malignancy was influenced by age or sex.
METHODS: We analyzed 463 nodules with an indeterminate cytological diagnosis of FN and 140 nodules with an indeterminate cytological diagnosis of HN. The histopathological diagnosis after thyroidectomy was the method for establishing the diagnosis and type of malignancy.
RESULTS: For the entire series of 603 patients there were 106 (17.6%) with thyroid cancer; 80 of these had a cytology reading of FN and 26 had HN. Extrathyroidal invasion in the grouped HN and FN patients who had papillary thyroid carcinoma (PTC) was more common in females than in males (62% vs. 25 %, p < 0.05). The rate of thyroid cancer was similar in FN (17.3%) and HN (18.6%). The rate of Hürthle cell thyroid cancer was significantly higher in HN than in FN (5.0% vs. 0.7%, p < 0.01) and the rate of the oncocytic variant of PTC was also significantly greater in HN compared to FN nodules (23.1% vs. 1.7%, p < 0.05). The rate of follicular thyroid carcinoma was almost identical in patients with HN and FN (19.2% vs. 18.8 %).
CONCLUSIONS: There is little difference in the rate of malignancy between thyroid nodules with a cytological reading of FN indeterminate for malignancy and HN indeterminate for malignancy but there is a difference in the types of thyroid cancers in these groups. Hürthle cell thyroid cancer and the oncocytic variant of PTC is more common in nodules with an HN indeterminate for malignancy cytology reading than in nodules with a FN indeterminate for malignancy cytology reading. Since Hürthle cell thyroid cancer and the oncocytic variant of PTC are more aggressive than other thyroid cancers, it is likely that patients with an HN indeterminate for malignancy cytology will, as a group, have more aggressive thyroid cancers than those with an FN indeterminate for malignancy cytology.

Entities:  

Mesh:

Year:  2009        PMID: 19355826     DOI: 10.1089/thy.2008.0338

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  21 in total

1.  Review of atypical cytology of thyroid nodule according to the Bethesda system and its beneficial effect in the surgical treatment of papillary carcinoma.

Authors:  Yoo Seung Chung; Changyoung Yoo; Ji Han Jung; Hyun Joo Choi; Young-Jin Suh
Journal:  J Korean Surg Soc       Date:  2011-08-03

2.  The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.

Authors:  Yin Ren; Natalia Kyriazidis; William C Faquin; Selen Soylu; Dipti Kamani; Rayan Saade; Nicole Torchia; Carrie Lubitz; Louise Davies; Nikolaos Stathatos; Antonia E Stephen; Gregory W Randolph
Journal:  Thyroid       Date:  2020-03       Impact factor: 6.568

3.  Prospective evaluation of acoustic radiation force impulse technology in the differentiation of thyroid nodules: accuracy and interobserver variability assessment.

Authors:  Hektor Grazhdani; Vito Cantisani; Pietro Lodise; Giorgio Di Rocco; Maria Cristina Proietto; Eloisa Fioravanti; Antonello Rubini; Adriano Redler
Journal:  J Ultrasound       Date:  2014-01-09

4.  Follicular nodules (THY3) of the thyroid: we recommend surgery.

Authors:  R G Gheri; E Romoli; V Vezzosi; B Ragghianti; S Bianchi; S Pedercini; F Dainelli; R Panconesi
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

5.  The predictive value of dominant nodules and the management of indeterminate group in multinodular goiter.

Authors:  Engin Acıoğlu; Özgür Yiğit; Nihal Seden; Gülben Erdem Huq
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-11       Impact factor: 2.503

Review 6.  Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis.

Authors:  Pierpaolo Trimboli; Giorgio Treglia; Leo Guidobaldi; Enrico Saggiorato; Giuseppe Nigri; Anna Crescenzi; Francesco Romanelli; Fabio Orlandi; Stefano Valabrega; Ramin Sadeghi; Luca Giovanella
Journal:  Endocrine       Date:  2013-10-03       Impact factor: 3.633

7.  The frequency of malignancy and the relationship between malignancy and ultrasonographic features of thyroid nodules with indeterminate cytology.

Authors:  Yasemin Tutuncu; Dilek Berker; Serhat Isik; Gulhan Akbaba; Ufuk Ozuguz; Ferit Kerim Kucukler; Erdal Göcmen; Yavuz Yalcın; Yusuf Aydin; Serdar Guler
Journal:  Endocrine       Date:  2013-03-17       Impact factor: 3.633

8.  Malignancy risk for solitary and multiple nodules in Hürthle cell-predominant thyroid fine-needle aspirations: A multi-institutional study.

Authors:  Kristine S Wong; Vickie Y Jo; Alarice C Lowe; William C Faquin; Andrew A Renshaw; Akeesha A Shah; Michael H Roh; Edward B Stelow; Jeffrey F Krane
Journal:  Cancer Cytopathol       Date:  2019-11-21       Impact factor: 5.284

9.  Quantitative Analysis of Galectin-3 Expression in Benign and Malignant Thyroid Nodules.

Authors:  Ivan Šamija; Neven Mateša; Sanja Tadinac; Tomislav Jukić
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780

10.  Q-elastography in the presurgical diagnosis of thyroid nodules with indeterminate cytology.

Authors:  Vito Cantisani; Salvatore Ulisse; Eleonora Guaitoli; Corrado De Vito; Riccardo Caruso; Renzo Mocini; Vito D'Andrea; Valeria Ascoli; Alfredo Antonaci; Carlo Catalano; Francesco Nardi; Adriano Redler; Paolo Ricci; Enrico De Antoni; Salvatore Sorrenti
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.